Drugs / DCVax(TM)-Prostate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00043212 | — | prostate cancer | Northwest Biotherapeutics | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCVax(TM)-Prostate | “A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating DCVax(tm)-Prostate, Autologous Dendritic Cells Loaded With Recombinant PSMA for the Treatment...” NCT00043212 ↗1“Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.” NCT00043212 ↗ |
| Action | Deplete | “This may help the immune system destroy prostate cancer cells.” NCT00043212 ↗ |
| Modality | Cell therapy | “Autologous Dendritic Cells Loaded With Recombinant PSMA” NCT00043212 ↗ |